Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1818.53
OMPI's Cash to Debt is ranked lower than
64% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. OMPI: 1818.53 )
OMPI' s 10-Year Cash to Debt Range
Min: 0.05   Max: No Debt
Current: 1818.53

Equity to Asset 0.66
OMPI's Equity to Asset is ranked lower than
75% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. OMPI: 0.66 )
OMPI' s 10-Year Equity to Asset Range
Min: -0.82   Max: 0.71
Current: 0.66

-0.82
0.71
Interest Coverage 1959.20
OMPI's Interest Coverage is ranked lower than
134% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OMPI: 1959.20 )
OMPI' s 10-Year Interest Coverage Range
Min: 2   Max: 1000
Current: 1959.2

2
1000
F-Score: 6
Z-Score: 16.58
M-Score: -2.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 22.70
OMPI's Operating margin (%) is ranked lower than
73% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. OMPI: 22.70 )
OMPI' s 10-Year Operating margin (%) Range
Min: 7.6   Max: 38
Current: 22.7

7.6
38
Net-margin (%) 13.80
OMPI's Net-margin (%) is ranked lower than
73% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. OMPI: 13.80 )
OMPI' s 10-Year Net-margin (%) Range
Min: 2.5   Max: 25
Current: 13.8

2.5
25
ROE (%) 26.90
OMPI's ROE (%) is ranked lower than
70% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. OMPI: 26.90 )
OMPI' s 10-Year ROE (%) Range
Min: 15.7   Max: 252.1
Current: 26.9

15.7
252.1
ROA (%) 20.30
OMPI's ROA (%) is ranked lower than
64% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. OMPI: 20.30 )
OMPI' s 10-Year ROA (%) Range
Min: 3.3   Max: 28.9
Current: 20.3

3.3
28.9
ROC (Joel Greenblatt) (%) 153.60
OMPI's ROC (Joel Greenblatt) (%) is ranked lower than
65% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. OMPI: 153.60 )
OMPI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 65.9   Max: 241.5
Current: 153.6

65.9
241.5
Revenue Growth (%) 8.60
OMPI's Revenue Growth (%) is ranked lower than
97% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. OMPI: 8.60 )
OMPI' s 10-Year Revenue Growth (%) Range
Min: -0.2   Max: 14.4
Current: 8.6

-0.2
14.4
EBITDA Growth (%) 13.70
OMPI's EBITDA Growth (%) is ranked lower than
96% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. OMPI: 13.70 )
OMPI' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 50.5
Current: 13.7

0
50.5
EPS Growth (%) 15.00
OMPI's EPS Growth (%) is ranked lower than
93% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. OMPI: 15.00 )
OMPI' s 10-Year EPS Growth (%) Range
Min: -10.6   Max: 15
Current: 15

-10.6
15
» OMPI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2012

OMPI Guru Trades in Q3 2012

Jim Simons 490,800 sh (+106.05%)
Joel Greenblatt 81,754 sh (-18.31%)
Chuck Royce 546,361 sh (-58.35%)
» More
Q4 2012

OMPI Guru Trades in Q4 2012

Chuck Royce 547,461 sh (+0.2%)
Joel Greenblatt Sold Out
Jim Simons 425,600 sh (-13.28%)
» More
Q1 2013

OMPI Guru Trades in Q1 2013

Mario Gabelli 587,200 sh (New)
Jean-Marie Eveillard 227,620 sh (New)
Jim Simons 236,400 sh (-44.45%)
Chuck Royce 5,819 sh (-98.94%)
» More
Q2 2013

OMPI Guru Trades in Q2 2013

Chuck Royce Sold Out
Jean-Marie Eveillard Sold Out
Mario Gabelli Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with OMPI

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-03-31 New Buy0.02%$13.48 - $19.8 $ 0.42-97%227620
Joel Greenblatt 2012-12-31 Sold Out 0.07%$11.94 - $13.78 $ 0.42-97%0
Joel Greenblatt 2012-06-30 Add 711.51%0.1%$12.03 - $14.6 $ 0.42-97%100075
Joel Greenblatt 2012-03-31 New Buy0.01%$10.1 - $13.71 $ 0.42-96%12332
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 13.50
OMPI's P/E(ttm) is ranked lower than
207% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 28.60 vs. OMPI: 13.50 )
OMPI' s 10-Year P/E(ttm) Range
Min: 8.45   Max: 57.79
Current: 13.5

8.45
57.79
P/B 3.49
OMPI's P/B is ranked lower than
72% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. OMPI: 3.49 )
OMPI' s 10-Year P/B Range
Min: 1.45   Max: 20.54
Current: 3.49

1.45
20.54
P/S 1.88
OMPI's P/S is ranked lower than
74% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. OMPI: 1.88 )
OMPI' s 10-Year P/S Range
Min: 0.89   Max: 5.03
Current: 1.88

0.89
5.03
PFCF 12.78
OMPI's PFCF is ranked lower than
281% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 30.00 vs. OMPI: 12.78 )
OMPI' s 10-Year PFCF Range
Min: 7.95   Max: 38.21
Current: 12.78

7.95
38.21
EV-to-EBIT 13.98
OMPI's EV-to-EBIT is ranked lower than
122% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. OMPI: 13.98 )
OMPI' s 10-Year EV-to-EBIT Range
Min: 4.1   Max: 24.5
Current: 13.98

4.1
24.5
PEG 1.34
OMPI's PEG is ranked lower than
417% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. OMPI: 1.34 )
OMPI' s 10-Year PEG Range
Min: 0.68   Max: 11.6
Current: 1.34

0.68
11.6
Shiller P/E 18.92
OMPI's Shiller P/E is ranked lower than
326% of the 175 Companies
in the Global Biotechnology industry.

( Industry Median: 38.74 vs. OMPI: 18.92 )
OMPI' s 10-Year Shiller P/E Range
Min: 16.8   Max: 38.52
Current: 18.92

16.8
38.52

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.50
OMPI's Price/Net Cash is ranked lower than
120% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. OMPI: 0.50 )
OMPI' s 10-Year Price/Net Cash Range
Min: 10.4   Max: 385
Current: 0.5

10.4
385
Price/Net Current Asset Value 0.40
OMPI's Price/Net Current Asset Value is ranked lower than
109% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. OMPI: 0.40 )
OMPI' s 10-Year Price/Net Current Asset Value Range
Min: 7.9   Max: 23.2
Current: 0.4

7.9
23.2
Price/Tangible Book 0.10
OMPI's Price/Tangible Book is ranked lower than
78% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. OMPI: 0.10 )
OMPI' s 10-Year Price/Tangible Book Range
Min: 3.3   Max: 26.4
Current: 0.1

3.3
26.4
Price/Graham Number 0.10
OMPI's Price/Graham Number is ranked lower than
235% of the 243 Companies
in the Global Biotechnology industry.

( Industry Median: 3.00 vs. OMPI: 0.10 )
OMPI' s 10-Year Price/Graham Number Range
Min: 1.4   Max: 6
Current: 0.1

1.4
6
Earnings Yield (Greenblatt) 7.20
OMPI's Earnings Yield (Greenblatt) is ranked lower than
151% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. OMPI: 7.20 )
OMPI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.1   Max: 24.6
Current: 7.2

4.1
24.6
Forward Rate of Return (Yacktman) 7.22
OMPI's Forward Rate of Return (Yacktman) is ranked lower than
85% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. OMPI: 7.22 )
OMPI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -8.8   Max: 34.3
Current: 7.22

-8.8
34.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:O1P.Germany

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide